Lisanti Capital Growth, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Lisanti Capital Growth, LLC
- $371 Million
- Q4 2024
A detailed history of Lisanti Capital Growth, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Lisanti Capital Growth, LLC holds 82,700 shares of CRNX stock, worth $2.75 Million. This represents 1.14% of its overall portfolio holdings.
Number of Shares
82,700
Previous 108,575
23.83%
Holding current value
$2.75 Million
Previous $5.55 Million
23.76%
% of portfolio
1.14%
Previous 1.61%
Shares
6 transactions
Others Institutions Holding CRNX
# of Institutions
255Shares Held
89.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$302 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$231 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$207 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$204 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$180 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.79B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...